What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Single vs combination IV antibiotics

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 265 participants
Low

Oral antibiotics vs IV antibiotics

Time to next exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral antibiotics vs IV antibiotics

Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single vs combination IV antibiotics

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 146 participants
Low

Single vs combination IV antibiotics

Time to next exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Single vs combination IV antibiotics

Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nebulised antibiotics vs IV antibiotics

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Nebulised antibiotics vs IV antibiotics

Time to next exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nebulised antibiotics vs IV antibiotics

Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral antibiotics vs IV antibiotics

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Oral antibiotics vs IV antibiotics

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Tinzaparin vs placebo

Pain intensityNumeric pain scale · people with sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low

Dalteparin vs placebo

Pain intensityVAS 0‐10. Scale from: 0 to 10. · sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 35 participants
Very low

Dalteparin vs placebo

Pain duration ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

The requirement for opiate treatment · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Number of serious complications of SCD ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Number of other sickle‐related events ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Hospitalisation (number and duration) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found